FGFR1 and pancreatic neoplasm: For instance, Bailey and colleagues demonstrated that KrasG12D/+;Trp53fl/+ mutant subtype (containing group of genes with FGFR1 expression) showed less aggressive clinical outcome compared to KrasG12D/+;Trp53fl/+;TAp63fl/fl mutant subtype (containing group of genes without FGFR1 expression) in pancreatic cancer [21].